Doug Brunk is a San Diego-based award-winning reporter who began covering health care in 1991. Before joining the company, he wrote for the health sciences division of Columbia University and was an associate editor at Contemporary Long Term Care magazine when it won a Jesse H. Neal Award. His work has been syndicated by the Los Angeles Times and he is the author of two books related to the University of Kentucky Wildcats men's basketball program. Doug has a master’s degree in magazine journalism from the S.I. Newhouse School of Public Communications at Syracuse University. Follow him on Twitter @dougbrunk.
News
Impact of Pregnancy on Rosacea Unpredictable, Study Suggests
Researchers conducted a telephone survey of 39 women diagnosed with rosacea prior to becoming pregnant who were admitted to Oregon Health &...
News
Study Identifies Cardiovascular Comorbidities Associated With Dermatomyositis
"Our findings are important both for prognosis and clinical care," the authors concluded.
News
FDA Gives Nod to Berdazimer Gel for Molluscum Contagiosum
Approval of berdazimer, a topical nitric oxide–releasing agent, was based largely on a 12-week pivotal phase 3 trial known as B-SIMPLE4.
News
AAAAI/ACAAI Joint Task Force Issues Updated ‘Practice-Changing’ Guidelines to Manage AD
“There’s something in here for all clinicians — from primary care to AD experts — and patients may benefit as well, so the key individual...
News
Expert Highlights Biologics in the Pipeline for Atopic Dermatitis
“It’s truly an exciting time because we have a lot of different treatments that target IL-4 and other receptors,” Dr. David Rosmarin said.
News
US Dermatologic Drug Approvals Rose Between 2012 and 2022
The study authors identified 52 new drug applications and 26 supplemental new indications approved by the FDA for dermatologic indications between...
News
Which Tools Are Best to Streamline In-Office Assessments of Eczema Patients?
Choose an assessment tool that works for you within your practice setting.
News
Experimental Topical Drug Shows Promise for Atopic Dermatitis and Plaque Psoriasis
PDE4 inhibitors are a promising therapeutic target for inflammatory diseases because “they can increase cyclic adenosine monophosphate levels and...
News
Expert Frames Factors to Consider Among Atopic Dermatitis Treatment Options
“There isn’t going to be a one-size-fits-all approach.”
News
‘Milestone’ Study Zeros in on 5-Year Safety Data From Upadacitinib Trials
“This is the longest safety study ever published for any systemic drug for AD,” Christopher G. Bunick, MD, said.
News
What’s the Real Prevalence of Conjunctivitis in AD Patients Treated With Dupilumab?
“About 2% of people treated with dupilumab are going to get clinically very meaningful conjunctivitis that may be therapy limiting.”
News
‘Real-World’ Registry Study of Upadacitinib Supports Clinical Trial Data
“We know from clinical trials that upadacitinib is effective, but we have very little real-world experience on its effectiveness,”...
News
What Makes Patients Vulnerable to Delusions of Parasitosis?
"Changes in health care, such as the dramatic increase in stimulant prescriptions and alternatives to opioids in pain management, may be...
News
FDA Approves Topical Gel For Wounds Associated With JEB and DEB
The FDA has approved a topical gel containing birch triterpenes for the treatment of partial thickness wounds in patients 6 months and older with...
News
How does lebrikizumab perform across different racial and ethnic subgroups?
Prior use of systemic therapy was lower in the Black and “other” subgroups, compared with other racial subgroups.